Gene study aims to personalize common heart drug
NCT ID NCT03051282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how genetic differences affect the activation of enalapril, a common blood pressure medication. Researchers gave 21 healthy volunteers enalapril for a week and measured drug levels in their blood. The goal was to see if a specific gene variant (G143E) changes how the body processes the drug, which could lead to more personalized dosing in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enalapril
- What this could lead to
- If successful, this could help doctors personalize ACE inhibitor dosing based on a person's genetics, improving effectiveness and reducing side effects.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. Results may not translate to real-world treatment or account for other factors affecting drug response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults